United Therapeutics Corporation to Present at the UBS Biopharma Conference 2023
31 Outubro 2023 - 7:00AM
Business Wire
United Therapeutics Corporation (Nasdaq: UTHR), a public
benefit corporation, announced today that Patrick Poisson,
Executive Vice President, Technical Operations, will provide an
overview and update on the company’s business during a fireside
chat session at the UBS Biopharma Conference 2023 in Miami Beach,
Florida.
The session will take place on Wednesday, November 8, 2023, from
10:00 a.m. to 10:25 a.m., Eastern Standard Time, and can be
accessed via a live webcast on the United Therapeutics website at
https://ir.unither.com/events-and-presentations. An archived,
recorded version of the session will be available approximately 24
hours after the session ends and can be accessed for 180 days.
United Therapeutics: Enabling Inspiration At United
Therapeutics, our vision and mission are one. We use our
enthusiasm, creativity, and persistence to innovate for the unmet
medical needs of our patients and to benefit our other
stakeholders. We are bold and unconventional. We have fun, we do
good. We are the first publicly-traded biotech or pharmaceutical
company to take the form of a public benefit corporation
(PBC). Our public benefit purpose is to provide a brighter
future for patients through (a) the development of novel
pharmaceutical therapies; and (b) technologies that expand the
availability of transplantable organs.
You can learn more about what it means to be a PBC here:
unither.com/pbc.
Forward-Looking Statements Statements included in this
press release that are not historical in nature are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements include, among others, our efforts to innovate for the
unmet medical needs of our patients, to benefit our other
stakeholders, and to pursue our public benefit purpose of
developing novel pharmaceutical therapies and technologies that
expand the availability of transplantable organs. These
forward-looking statements are subject to certain risks and
uncertainties, such as those described in our periodic reports
filed with the Securities and Exchange Commission, that could cause
actual results to differ materially from anticipated results.
Consequently, such forward-looking statements are qualified by the
cautionary statements, cautionary language, and risk factors set
forth in our periodic reports and documents filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K. We claim the protection of the safe
harbor contained in the Private Securities Litigation Reform Act of
1995 for forward-looking statements. We are providing this
information as of October 31, 2023 and assume no obligation to
update or revise the information contained in this press release
whether as a result of new information, future events or any other
reason.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031325629/en/
Dewey Steadman at (202) 919-4097
https://ir.unither.com/contact-uthr/
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024